Market Overview
On Tuesday, the S&P/ASX 200 Index (ASX: XJO) experienced a decline of 0.5%, settling at 8,725.3 points. Among the 11 market sectors, only the energy sector managed to stay in positive territory, rising by 0.3% as Brent Crude oil prices climbed to $108 per barrel. In contrast, the utilities sector suffered the most significant drop, falling by 3.6%. Additionally, ASX 200 consumer discretionary shares also declined by 1.2%, with investors anticipating the release of the crucial quarterly inflation report tomorrow.
Expert Insights on ASX 200 Shares
This week, The Bull featured insights from two experts who shared their perspectives on three ASX 200 shares. Let’s explore these recommendations in detail.
Sigma Healthcare Ltd (ASX: SIG)
Sigma Healthcare’s share price is currently at $2.76, marking a 0.5% decrease on Tuesday and an 11% decline over the past six months. The stock reached a record high of $3.28 in June 2025 before experiencing a prolonged downturn alongside the broader sector.
Damien Nguyen from Morgans has assigned a buy rating to this healthcare share. His rationale includes:
- A solid balance sheet with conservative leverage and strong operating cash flows.
- Potential for margin expansion through the growth of labels it owns and exclusive products.
- Expectations of improved operating leverage due to supply chain efficiencies and consolidation in distribution centers.
- A softer share price presents a compelling buying opportunity for long-term focused investors.
Macquarie Group Ltd (ASX: MQG)
The Macquarie share price stands at $231.15, reflecting a 0.4% decrease today but a 16% increase over the past month. Damien Nguyen has a hold rating on this bank share. He highlights:
- Macquarie is a diversified financial services group with strengths across asset management, infrastructure, and global markets.
- Its business model benefits from long-term infrastructure investment and energy transition themes, although earnings can be volatile due to market conditions.
- Recent performance has been solid, with much of the medium-term opportunity already reflected in the share price.
- While Macquarie remains a high-quality company with strong management, near-term upside is balanced by cyclical and market risks. At current levels, a hold is appropriate.
Macquarie is set to release its full-year FY26 results on Friday, 8 May.
Santos Ltd (ASX: STO)
Santos’ share price is $7.73, showing a 1% increase on Tuesday and a 26% rise year-to-date (YTD). Most of this YTD gain is attributed to the surge in oil and gas prices, driven by the ongoing Iran conflict.
Stuart Bromley from Medallion Financial Group has issued a sell rating for this global energy giant. His reasoning includes:
- A recommendation to lock in gains given the volatile and uncertain energy prices stemming from the Middle East conflict.
- Santos shares have risen from $5.92 on 7 January to $7.73 today.
- For full-year FY25, Santos reported an 8% fall in revenue due to lower realized prices and a 33% drop in net profit after tax (NPAT).
Additional Information
The article “Buy, hold, sell: Sigma Healthcare, Macquarie, Santos shares” originally appeared on The Motley Fool Australia. Before considering an investment in Santos, potential investors should take into account expert advice. Motley Fool investing expert Scott Phillips recently highlighted what he believes are the 5 best stocks for investors to consider right now, and Santos was not among them.
For more information, readers can explore additional articles such as “Buy, hold, sell: Macquarie, Boss Energy, CBA shares,” “5 things to watch on the ASX 200 on Tuesday,” and “Why I think these high-quality ASX shares deserve a spot in most investment portfolios.”
Disclosure
Bronwyn Allen, the Motley Fool contributor, has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company, Motley Fool Holdings Inc., has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
